Brain Integrity in Survivors of Hodgkin Lymphoma Treated With Thoracic Radiation
| Status: | Completed |
|---|---|
| Conditions: | Lymphoma |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/17/2018 |
| Start Date: | April 26, 2013 |
| End Date: | February 20, 2018 |
Brain Integrity in Survivors of Hodgkin Lymphoma (HL) Treated With Thoracic Radiation
While thoracic radiation therapy (TRT) has been a primary component in successful treatment
of a variety of childhood and adult cancers, the exposure to this treatment has been
associated with significant cardiovascular and pulmonary morbidity in long-term survivors.
Within non-cancer populations, cardiovascular and pulmonary morbidity is associated with
increased risk for cerebral vascular accidents (CVAs), accelerated brain atrophy and
neurocognitive impairment. Patients with chronic heart disease demonstrate problems with
attention, processing speed, memory, and executive functions. Chronic pulmonary disease also
increases the risk of stroke, leukoencephalopathy, and neurocognitive impairment in
non-cancer populations. The investigators propose to examine indices of brain integrity,
including neurocognitive performance and brain MRI/MRA, in long-term adult survivors of
Hodgkin lymphoma (HL) treated with thoracic radiation and no direct central nervous system
therapy.
OBJECTIVES:
1. To evaluate brain integrity in adult survivors of childhood HL treated with thoracic
radiation therapy.
2. To identify therapeutic factors associated with brain integrity in adult survivors of
childhood HL who are at risk for cardiac and pulmonary morbidity.
3. To examine associations between cardiac, vascular and pulmonary health and brain
integrity in adult survivors of childhood HL treated with thoracic radiation.
of a variety of childhood and adult cancers, the exposure to this treatment has been
associated with significant cardiovascular and pulmonary morbidity in long-term survivors.
Within non-cancer populations, cardiovascular and pulmonary morbidity is associated with
increased risk for cerebral vascular accidents (CVAs), accelerated brain atrophy and
neurocognitive impairment. Patients with chronic heart disease demonstrate problems with
attention, processing speed, memory, and executive functions. Chronic pulmonary disease also
increases the risk of stroke, leukoencephalopathy, and neurocognitive impairment in
non-cancer populations. The investigators propose to examine indices of brain integrity,
including neurocognitive performance and brain MRI/MRA, in long-term adult survivors of
Hodgkin lymphoma (HL) treated with thoracic radiation and no direct central nervous system
therapy.
OBJECTIVES:
1. To evaluate brain integrity in adult survivors of childhood HL treated with thoracic
radiation therapy.
2. To identify therapeutic factors associated with brain integrity in adult survivors of
childhood HL who are at risk for cardiac and pulmonary morbidity.
3. To examine associations between cardiac, vascular and pulmonary health and brain
integrity in adult survivors of childhood HL treated with thoracic radiation.
This is an observational study to collect health data from long-term survivors of Hodgkin
lymphoma (HL). Data will be collected once at participant enrollment. The long-term effects
of thoracic radiation therapy (TRT) given earlier as part of the treatment for HL will be
examined in long-term survivors and compared to health data collected from normal volunteers.
HL survivors who were treated at St. Jude Children's Research Hospital (SJCRH) with TRT will
be recruited to complete a comprehensive neurocognitive evaluation, brain MRI/MRA, a clinical
neurological exam, peripheral pulse contour analysis, non-invasive central blood pressure
monitoring, cardiopulmonary exercise testing, and serum biomarkers related to cardiac
disease. As part of their standard St. Jude LIFE protocol evaluation, they also complete an
echocardiogram, pulmonary function tests and questionnaires designed to evaluate broad
health, psychological, socioeconomic and environmental factors that impact everyday life.
A comparison sample of healthy individuals, frequency-matched on age, sex and race will also
be recruited. The comparison group will complete the comprehensive neurocognitive evaluation,
brain MRI/MRA, clinical neurological exam, pulse contour analysis, non-invasive central blood
pressure monitoring, and cardiopulmonary exercise testing. Through the St. Jude LIFE
protocol, the comparison sample will also complete an echocardiogram, pulmonary function
tests and questionnaires designed to evaluate broad health, psychological, socioeconomic and
environmental factors that impact everyday life.
lymphoma (HL). Data will be collected once at participant enrollment. The long-term effects
of thoracic radiation therapy (TRT) given earlier as part of the treatment for HL will be
examined in long-term survivors and compared to health data collected from normal volunteers.
HL survivors who were treated at St. Jude Children's Research Hospital (SJCRH) with TRT will
be recruited to complete a comprehensive neurocognitive evaluation, brain MRI/MRA, a clinical
neurological exam, peripheral pulse contour analysis, non-invasive central blood pressure
monitoring, cardiopulmonary exercise testing, and serum biomarkers related to cardiac
disease. As part of their standard St. Jude LIFE protocol evaluation, they also complete an
echocardiogram, pulmonary function tests and questionnaires designed to evaluate broad
health, psychological, socioeconomic and environmental factors that impact everyday life.
A comparison sample of healthy individuals, frequency-matched on age, sex and race will also
be recruited. The comparison group will complete the comprehensive neurocognitive evaluation,
brain MRI/MRA, clinical neurological exam, pulse contour analysis, non-invasive central blood
pressure monitoring, and cardiopulmonary exercise testing. Through the St. Jude LIFE
protocol, the comparison sample will also complete an echocardiogram, pulmonary function
tests and questionnaires designed to evaluate broad health, psychological, socioeconomic and
environmental factors that impact everyday life.
Inclusion Criteria - HL participant:
- Current St. Jude LIFE protocol Participant, treated with thoracic radiation
- Currently ≥ 18 years of age
- ≥ 10 years from original diagnosis
Exclusion Criteria - HL participant:
- Has participated in the previous pilot study at St. Jude (HPP16)
- History of cranial or total-body radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with
neurocognitive impairment
- Pre-existing known neurocognitive impairment prior to diagnosis of Hodgkin lymphoma
- History of congenital heart disease reported in the literature to be associated with
neurocognitive status as determined by the principal investigators
- Currently pregnant
- Secondary central nervous system neoplasm
Inclusion Criteria - Normal Control:
- Research participant is a sibling, parent, relative or friend of a current or former
St. Jude patient
- Research participant must be at least 18 years of age at the time of the scheduled
evaluation
Exclusion Criteria - Normal Control:
- History of cranial, total-body or thoracic radiation therapy
- History of intrathecal Methotrexate, high-dose Methotrexate, or high-dose Cytarabine.
- History of head injury or diagnosis of a genetic disorder associated with
neurocognitive impairment
- Known neurocognitive impairment
- History of congenital heart disease reported in the literature to be associated with
neurocognitive status as determined by the principal investigators
- Currently pregnant
- Central nervous system neoplasm
We found this trial at
1
site
262 Danny Thomas Pl
Memphis, Tennessee 38105
Memphis, Tennessee 38105
(901) 495-3300
Principal Investigator: Kevin Krull, PhD
Phone: 866-278-5833
St. Jude Children's Research Hospital St. Jude is unlike any other pediatric treatment and research...
Click here to add this to my saved trials
